Oncology & Cancer

Avastin no benefit to older lung cancer patients: study

(HealthDay) -- Medicare patients who have advanced non-small cell lung cancer appear to get no survival benefit from adding the drug Avastin to standard chemotherapy, researchers from the Dana-Farber Cancer Institute report.

Oncology & Cancer

FDA panel backs Glaxo drug for rare sarcoma cancer

(AP) -- A panel of cancer experts overwhelmingly backed the approval of a GlaxoSmithKline drug for a rare type of tumor, noting there are few other treatment options for patients.

Oncology & Cancer

Vandetanib doesn't up survival in non-small-cell lung cancer

(HealthDay) -- Vandetanib does not improve overall survival for patients who have received previous treatment for advanced non-small-cell lung cancer (NSCLC), according to a study published online Feb. 27 in the Journal of ...

Oncology & Cancer

Lung cancer patients with diabetes show prolonged survival

Lung cancer patients with diabetes tend to live longer than patients without diabetes, according to a Norwegian study published in the November issue of the Journal of Thoracic Oncology, the official publication of the International ...

page 9 from 10